BioNTech to Report Third Quarter Financial Results and Operational Update on November 9, 2021
BioNTech to Report Third Quarter Financial Results and Operational Update on November 9, 2021
Mainz, Germany, October 27, 2021 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, "BioNTech" or "the Company") will announce its financial results for the third quarter on Tuesday, November 9th, 2021. BioNTech invites investors and the general public to join a conference call and webcast with investment analysts on the same day at 8.00 a.m. ET (2.00 p.m. CET) to report its financial results and provide a corporate update for the third quarter 2021.
德國美因茨，2021年10月27日 (環球通訊社)--BioNTech SE(納斯達克市場代碼：BNTX，“BioNTech”或“The Company”)將於11月9日(星期二)公佈第三季度財務業績，2021年。BioNTech邀請投資者和普通公眾參加當天上午8點與投資分析師舉行的電話會議和網絡直播。美國東部時間(下午2點)CET(CET：行情)報告其財務業績，並提供2021年第三季度的公司最新情況。
The slide presentation and audio of the webcast will be available via this link.
網絡廣播的幻燈片演示文稿和音頻將通過此鏈接提供。
To participate in the conference call, please dial the following numbers ten minutes prior to the start and provide the Conference ID:
要參加電話會議，請在會議開始前10分鐘撥打以下號碼並提供會議ID：
| United States international: United States domestic (toll-free): Germany: Conference ID: |
+1 646 741 3167 +1 877 870 9135 +49 (0) 692 2222 625 6835174 |
| 美國國際： 美國國內(免費)： 德國： 會議ID： |
+1 646 741 3167 +1 877 870 9135 +49 (0) 692 2222 625 6835174 |
Participants may also access the slides and the webcast of the conference call via the "Events & Presentations" page of the Investor Relations section of the Company's website at https://biontech.de/. A replay of the webcast will be available shortly after the conclusion of the call and archived on the Company's website for 30 days following the call.
與會者還可以通過公司網站https://biontech.de/.投資者關係部的“活動和演示”頁面訪問電話會議的幻燈片和網絡直播。電話會議結束後不久，將可收看網絡直播的重播，並在電話會議結束後30天內在公司網站上存檔。
About BioNTech
Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer.
關於BioNTech生物製藥新技術公司是下一代免疫治療公司，致力於開創癌症和其他嚴重疾病的新療法。該公司利用廣泛的計算髮現和治療藥物平臺來快速開發新型生物製藥。其廣泛的腫瘤學候選產品組合包括個性化和現成的基於mRNA的療法、創新的嵌合抗原受體T細胞、雙特異性檢查點免疫調節劑、靶向癌症抗體和小分子。基於其在mRNA疫苗開發和內部製造能力方面的深厚專業知識，BioNTech及其合作者在其多樣化的腫瘤學流水線的同時，正在為一系列傳染病開發多種候選mRNA疫苗。BioNTech已經與多家全球製藥合作伙伴建立了廣泛的關係，其中包括Genmab、賽諾菲、拜耳動物健康公司、羅氏集團成員基因泰克、Regeneron、Genevant、復星國際製藥公司和輝瑞公司。
For more information, please visit www.BioNTech.de.
欲瞭解更多信息，請訪問www.BioNTech.de。
BioNTech Contacts
BioNTech聯繫人
Investor Relations
Sylke Maas, Ph.D.
+49 (0)6131 9084 1074
Investors@biontech.de
投資者關係西爾克·馬斯(Sylke Maas)，博士。+49 (0)6131 9084 1074郵箱：Investors@biontech.de
Media Relations
Jasmina Alatovic
+49 (0)6131 9084 1513
Media@biontech.de
媒體關係茉莉·阿拉託維奇(Jasmina Alatovic)+49 (0)6131 9084 1513郵箱：media@biontech.de
譯文內容由第三人軟體翻譯。